Search

Your search keyword '"Simicek, Michal"' showing total 151 results
Start Over Author "Simicek, Michal"
151 results on '"Simicek, Michal"'

3. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

Author

Jelinek, Tomas, Sevcikova, Tereza, Zihala, David, Popkova, Tereza, Kapustova, Veronika, Broskevicova, Lucie, Capkova, Lenka, Rihova, Lucie, Bezdekova, Renata, Sevcikova, Sabina, Zidlik, Vladimir, Havel, Martin, Plonkova, Hana, Jungova, Alexandra, Minarik, Jiri, Stork, Martin, Pour, Ludek, Pavlicek, Petr, Spicka, Ivan, Maisnar, Vladimir, Radocha, Jakub, Simicek, Michal, and Hajek, Roman

Published
2022
Full Text
View/download PDF

5. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

Author

Garcés, Juan-Jose, Simicek, Michal, Vicari, Marco, Brozova, Lucie, Burgos, Leire, Bezdekova, Renata, Alignani, Diego, Calasanz, Maria-Jose, Growkova, Katerina, Goicoechea, Ibai, Agirre, Xabier, Pour, Ludek, Prosper, Felipe, Rios, Rafael, Martinez-Lopez, Joaquin, Millacoy, Pamela, Palomera, Luis, Del Orbe, Rafael, Perez-Montaña, Albert, Garate, Sonia, Blanco, Laura, Lasa, Marta, Maiso, Patricia, Flores-Montero, Juan, Sanoja-Flores, Luzalba, Chyra, Zuzana, Vdovin, Alexander, Sevcikova, Tereza, Jelinek, Tomas, Botta, Cirino, El Omri, Halima, Keats, Jonathan, Orfao, Alberto, Hajek, Roman, San-Miguel, Jesus F., and Paiva, Bruno

Published
2020
Full Text
View/download PDF

7. Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti‐CD38 therapy

Author

Venglar, Ondrej, primary, Kapustova, Veronika, additional, Anilkumar Sithara, Anjana, additional, Zihala, David, additional, Muronova, Ludmila, additional, Sevcikova, Tereza, additional, Vrana, Jan, additional, Vdovin, Alexander, additional, Radocha, Jakub, additional, Krhovska, Petra, additional, Hrdinka, Matous, additional, Turjap, Michal, additional, Popkova, Tereza, additional, Chyra, Zuzana, additional, Broskevicova, Lucie, additional, Simicek, Michal, additional, Koristek, Zdenek, additional, Hajek, Roman, additional, and Jelinek, Tomas, additional

Published
2023
Full Text
View/download PDF

8. Insight into the mechanism of CD34+ cell mobilisation impairment in multiple myeloma patients treated with anti‐CD38 therapy.

Author

Venglar, Ondrej, Kapustova, Veronika, Anilkumar Sithara, Anjana, Zihala, David, Muronova, Ludmila, Sevcikova, Tereza, Vrana, Jan, Vdovin, Alexander, Radocha, Jakub, Krhovska, Petra, Hrdinka, Matous, Turjap, Michal, Popkova, Tereza, Chyra, Zuzana, Broskevicova, Lucie, Simicek, Michal, Koristek, Zdenek, Hajek, Roman, and Jelinek, Tomas

Subjects
MULTIPLE myeloma, CD34 antigen, BONE products, AUTOTRANSPLANTATION, HEPATOCELLULAR carcinoma, BONE marrow
Abstract

Summary: Induction therapy followed by CD34+ cell mobilisation and autologous transplantation represents standard of care for multiple myeloma (MM). However, the anti‐CD38 monoclonal antibodies daratumumab and isatuximab have been associated with mobilisation impairment, yet the mechanism remains unclear. In this study, we investigated the effect of three different regimens (dara‐VCd, isa‐KRd and VTd) on CD34+ cells using flow cytometry and transcriptomics. Decreased CD34+ cell peak concentration and yields, longer collection and delayed engraftment were reproduced after dara‐VCd/isa‐KRd versus VTd induction in 34 patients in total. Using flow cytometry, we detected major changes in the proportion of apheresis product and bone marrow CD34+ subsets in patients treated with regimens containing anti‐CD38 therapy; however, without any decrease in CD38high B‐lymphoid progenitors in both materials. RNA‐seq of mobilised CD34+ cells from 21 patients showed that adhesion genes are overexpressed in CD34+ cells after dara‐VCd/isa‐KRd and JCAD, NRP2, MDK, ITGA3 and CLEC3B were identified as potential target genes. Finally, direct in vitro effect of isatuximab in upregulating JCAD and CLEC3B was confirmed by quantitative PCR. These findings suggest that upregulated adhesion‐related interactions, rather than killing of CD34+ cells by effector mechanisms, could be leading causes of decreased mobilisation efficacy in MM patients treated with anti‐CD38 therapy. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma

Author

Haertle, Larissa, Buenache, Natalia, Cuesta Hernández, Hipólito Nicolás, Simicek, Michal, Snaurova, Renata, Rapado, Inmaculada, Martinez, Nerea, López Muñoz, María de las Nieves, Sánchez Pina, José María, Munawar, Umair, Han, Seungbin, Ruiz Heredia, Yanira, Colmenares Gil, Rafael, Gallardo Delgado, Miguel, Sanchez Beato, Margarita, Piris, Miguel Angel, Samur, Mehmet Kemal, Munshi, Nikhil C., Ayala Díaz, Rosa María, Kortüm, Klaus Martin, Barrio, Santiago, Martínez López, Joaquín, Haertle, Larissa, Buenache, Natalia, Cuesta Hernández, Hipólito Nicolás, Simicek, Michal, Snaurova, Renata, Rapado, Inmaculada, Martinez, Nerea, López Muñoz, María de las Nieves, Sánchez Pina, José María, Munawar, Umair, Han, Seungbin, Ruiz Heredia, Yanira, Colmenares Gil, Rafael, Gallardo Delgado, Miguel, Sanchez Beato, Margarita, Piris, Miguel Angel, Samur, Mehmet Kemal, Munshi, Nikhil C., Ayala Díaz, Rosa María, Kortüm, Klaus Martin, Barrio, Santiago, and Martínez López, Joaquín

Abstract

This study was funded by Instituto de Salud Carlos III (ISCIII) and was co-funded by the European Union, through projects PI21/00314, PTQ2020-011372, and CP22/00082, and the CRIS Cancer Foundation. L.H. was funded by the DFG (Deutsche Forschungsgemeinschaft). through research fellowship HA 9529/1-1. M.K.S and N.C.M are funded by SPORE in Multiple Myeloma P50 CA100707 and Integrative Oncogenomics of Multiple Myeloma P01 CA155258. This work was furthermore supported by the project “Cell Coolab Ostrava—Research and Development Center for Cell Therapy in Hematology and Oncology” (No. C.Z.02.1.01/0.0/0.0/17_049/0008440) supported by ERDF., For the treatment of Multiple Myeloma, proteasome inhibitors are highly efficient and widely used, but resistance is a major obstacle to successful therapy. Several underlying mechanisms have been proposed but were only reported for a minority of resistant patients. The proteasome is a large and complex machinery. Here, we focus on the AAA ATPases of the 19S proteasome regulator (PSMC1-6) and their implication in PI resistance. As an example of cancer evolution and the acquisition of resistance, we conducted an in-depth analysis of an index patient by applying FISH, WES, and immunoglobulin-rearrangement sequencing in serial samples, starting from MGUS to newly diagnosed Multiple Myeloma to a PI-resistant relapse. The WES analysis uncovered an acquired PSMC2 Y429S mutation at the relapse after intensive bortezomib-containing therapy, which was functionally confirmed to mediate PI resistance. A meta-analysis comprising 1499 newly diagnosed and 447 progressed patients revealed a total of 36 SNVs over all six PSMC genes that were structurally accumulated in regulatory sites for activity such as the ADP/ATP binding pocket. Other alterations impact the interaction between different PSMC subunits or the intrinsic conformation of an individual subunit, consequently affecting the folding and function of the complex. Interestingly, several mutations were clustered in the central channel of the ATPase ring, where the unfolded substrates enter the 20S core. Our results indicate that PSMC SNVs play a role in PI resistance in MM., European Union, Instituto de Salud Carlos III (ISCIII), CRIS Cancer Foundation, Cell Coolab Ostrava—Research and Development Center for Cell Therapy in Hematology and Oncology, Depto. de Medicina, Fac. de Medicina, TRUE, pub

Published
2023

11. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma

Author

European Commission, Ministry of Health of the Czech Republic, Technical University of Ostrava, Ministry of Education, Youth and Sports (Czech Republic), Centro de Investigación Biomédica en Red Cáncer (España), Instituto de Salud Carlos III, Cancer Research UK, European Research Council, Jelínek, Tomáš, Bezdekova, Renata, Žihala, David, Sevcikova, Tereza, Anilkumar Sithara, Anjana, Pospisilova, Sarka, Sevcikova, Sabina, Polackova, Petra, Stork, Martin, Knechtova, Zdenka, Venglar, Ondrej, Kapustova, Veronika, Popkova, Tereza, Muronova, Ludmila, Chyra, Zuzana, Hrdinka, Matous, Simicek, Michal, Garcés, Juan José, Puig, Noemi, Cedena, Maria-Teresa, Jurczyszyn, Artur, Castillo, Jorge J., Penka, Miroslav, Radocha, Jakub, Mateos, Maria Victoria, San-Miguel, Jesús, Paiva, Bruno, Pour, Ludek, Rihova, Lucie, Hajek, Roman, European Commission, Ministry of Health of the Czech Republic, Technical University of Ostrava, Ministry of Education, Youth and Sports (Czech Republic), Centro de Investigación Biomédica en Red Cáncer (España), Instituto de Salud Carlos III, Cancer Research UK, European Research Council, Jelínek, Tomáš, Bezdekova, Renata, Žihala, David, Sevcikova, Tereza, Anilkumar Sithara, Anjana, Pospisilova, Sarka, Sevcikova, Sabina, Polackova, Petra, Stork, Martin, Knechtova, Zdenka, Venglar, Ondrej, Kapustova, Veronika, Popkova, Tereza, Muronova, Ludmila, Chyra, Zuzana, Hrdinka, Matous, Simicek, Michal, Garcés, Juan José, Puig, Noemi, Cedena, Maria-Teresa, Jurczyszyn, Artur, Castillo, Jorge J., Penka, Miroslav, Radocha, Jakub, Mateos, Maria Victoria, San-Miguel, Jesús, Paiva, Bruno, Pour, Ludek, Rihova, Lucie, and Hajek, Roman

Abstract

[Purpose]: Primary plasma cell leukemia (PCL) is the most aggressive monoclonal gammopathy. It was formerly characterized by $ 20% circulating plasma cells (CTCs) until 2021, when this threshold was decreased to $ 5%. We hypothesized that primary PCL is not a separate clinical entity, but rather that it represents ultra-high-risk multiple myeloma (MM) characterized by elevated CTC levels. [Methods]: We assessed the levels of CTCs by multiparameter flow cytometry in 395 patients with newly diagnosed transplant-ineligible MM to establish a cutoff for CTCs that identifies the patients with ultra-high-risk PCL-like MM. We tested the cutoff on 185 transplant-eligible patients with MM and further validated on an independent cohort of 280 transplant-ineligible patients treated in the GEM-CLARIDEX trial. The largest published real-world cohort of patients with primary PCL was used for comparison of survival. Finally, we challenged the current 5% threshold for primary PCL diagnosis. [Results]: Newly diagnosed transplant-ineligible patients with MM with 2%-20% CTCs had significantly shorter progression-free survival (3.1 v 15.6 months; P , .001) and overall survival (14.6 v 33.6 months; P 5 .023) than patients with , 2%. The 2% cutoff proved to be applicable also in transplant-eligible patients with MM and was successfully validated on an independent cohort of patients from the GEM-CLARIDEX trial. Most importantly, patients with 2%-20% CTCs had comparable dismal outcomes with primary PCL. Moreover, after revealing a low mean difference between flow cytometric and morphologic evaluation of CTCs, we showed that patients with 2%-5% CTCs have similar outcomes as those with 5%-20% CTCs. [Conclusions]: Our study uncovers that $ 2% CTCs is a biomarker of hidden primary PCL and supports the assessment of CTCs by flow cytometry during the diagnostic workup of MM.

Published
2023

12. Supplementary Table 3 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

Author

Haertle, Larissa, primary, Barrio, Santiago, primary, Munawar, Umair, primary, Han, Seungbin, primary, Zhou, Xiang, primary, Simicek, Michal, primary, Vogt, Cornelia, primary, Truger, Marietta, primary, Fernandez, Rafael Alonso, primary, Steinhardt, Maximilian, primary, Weingart, Julia, primary, Snaurova, Renata, primary, Nerreter, Silvia, primary, Teufel, Eva, primary, Garitano-Trojaola, Andoni, primary, Da Viá, Matteo, primary, Ruiz-Heredia, Yanira, primary, Rosenwald, Andreas, primary, Bolli, Niccolò, primary, Hajek, Roman, primary, Raab, Peter, primary, Raab, Marc S., primary, Weinhold, Niels, primary, Haferlach, Claudia, primary, Haaf, Thomas, primary, Martinez-Lopez, Joaquin, primary, Einsele, Hermann, primary, Rasche, Leo, primary, and Kortüm, K. Martin, primary

Published
2023
Full Text
View/download PDF

13. Supplementary Figure 3 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

Author

Haertle, Larissa, primary, Barrio, Santiago, primary, Munawar, Umair, primary, Han, Seungbin, primary, Zhou, Xiang, primary, Simicek, Michal, primary, Vogt, Cornelia, primary, Truger, Marietta, primary, Fernandez, Rafael Alonso, primary, Steinhardt, Maximilian, primary, Weingart, Julia, primary, Snaurova, Renata, primary, Nerreter, Silvia, primary, Teufel, Eva, primary, Garitano-Trojaola, Andoni, primary, Da Viá, Matteo, primary, Ruiz-Heredia, Yanira, primary, Rosenwald, Andreas, primary, Bolli, Niccolò, primary, Hajek, Roman, primary, Raab, Peter, primary, Raab, Marc S., primary, Weinhold, Niels, primary, Haferlach, Claudia, primary, Haaf, Thomas, primary, Martinez-Lopez, Joaquin, primary, Einsele, Hermann, primary, Rasche, Leo, primary, and Kortüm, K. Martin, primary

Published
2023
Full Text
View/download PDF

14. Supplementary Table 4 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

Author

Haertle, Larissa, primary, Barrio, Santiago, primary, Munawar, Umair, primary, Han, Seungbin, primary, Zhou, Xiang, primary, Simicek, Michal, primary, Vogt, Cornelia, primary, Truger, Marietta, primary, Fernandez, Rafael Alonso, primary, Steinhardt, Maximilian, primary, Weingart, Julia, primary, Snaurova, Renata, primary, Nerreter, Silvia, primary, Teufel, Eva, primary, Garitano-Trojaola, Andoni, primary, Da Viá, Matteo, primary, Ruiz-Heredia, Yanira, primary, Rosenwald, Andreas, primary, Bolli, Niccolò, primary, Hajek, Roman, primary, Raab, Peter, primary, Raab, Marc S., primary, Weinhold, Niels, primary, Haferlach, Claudia, primary, Haaf, Thomas, primary, Martinez-Lopez, Joaquin, primary, Einsele, Hermann, primary, Rasche, Leo, primary, and Kortüm, K. Martin, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure 2 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

Author

Haertle, Larissa, primary, Barrio, Santiago, primary, Munawar, Umair, primary, Han, Seungbin, primary, Zhou, Xiang, primary, Simicek, Michal, primary, Vogt, Cornelia, primary, Truger, Marietta, primary, Fernandez, Rafael Alonso, primary, Steinhardt, Maximilian, primary, Weingart, Julia, primary, Snaurova, Renata, primary, Nerreter, Silvia, primary, Teufel, Eva, primary, Garitano-Trojaola, Andoni, primary, Da Viá, Matteo, primary, Ruiz-Heredia, Yanira, primary, Rosenwald, Andreas, primary, Bolli, Niccolò, primary, Hajek, Roman, primary, Raab, Peter, primary, Raab, Marc S., primary, Weinhold, Niels, primary, Haferlach, Claudia, primary, Haaf, Thomas, primary, Martinez-Lopez, Joaquin, primary, Einsele, Hermann, primary, Rasche, Leo, primary, and Kortüm, K. Martin, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Figure 1 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

Author

Haertle, Larissa, primary, Barrio, Santiago, primary, Munawar, Umair, primary, Han, Seungbin, primary, Zhou, Xiang, primary, Simicek, Michal, primary, Vogt, Cornelia, primary, Truger, Marietta, primary, Fernandez, Rafael Alonso, primary, Steinhardt, Maximilian, primary, Weingart, Julia, primary, Snaurova, Renata, primary, Nerreter, Silvia, primary, Teufel, Eva, primary, Garitano-Trojaola, Andoni, primary, Da Viá, Matteo, primary, Ruiz-Heredia, Yanira, primary, Rosenwald, Andreas, primary, Bolli, Niccolò, primary, Hajek, Roman, primary, Raab, Peter, primary, Raab, Marc S., primary, Weinhold, Niels, primary, Haferlach, Claudia, primary, Haaf, Thomas, primary, Martinez-Lopez, Joaquin, primary, Einsele, Hermann, primary, Rasche, Leo, primary, and Kortüm, K. Martin, primary

Published
2023
Full Text
View/download PDF

17. Supplementary Figure 4 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

Author

Haertle, Larissa, primary, Barrio, Santiago, primary, Munawar, Umair, primary, Han, Seungbin, primary, Zhou, Xiang, primary, Simicek, Michal, primary, Vogt, Cornelia, primary, Truger, Marietta, primary, Fernandez, Rafael Alonso, primary, Steinhardt, Maximilian, primary, Weingart, Julia, primary, Snaurova, Renata, primary, Nerreter, Silvia, primary, Teufel, Eva, primary, Garitano-Trojaola, Andoni, primary, Da Viá, Matteo, primary, Ruiz-Heredia, Yanira, primary, Rosenwald, Andreas, primary, Bolli, Niccolò, primary, Hajek, Roman, primary, Raab, Peter, primary, Raab, Marc S., primary, Weinhold, Niels, primary, Haferlach, Claudia, primary, Haaf, Thomas, primary, Martinez-Lopez, Joaquin, primary, Einsele, Hermann, primary, Rasche, Leo, primary, and Kortüm, K. Martin, primary

Published
2023
Full Text
View/download PDF

18. Supplementary Table 1 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

Author

Haertle, Larissa, primary, Barrio, Santiago, primary, Munawar, Umair, primary, Han, Seungbin, primary, Zhou, Xiang, primary, Simicek, Michal, primary, Vogt, Cornelia, primary, Truger, Marietta, primary, Fernandez, Rafael Alonso, primary, Steinhardt, Maximilian, primary, Weingart, Julia, primary, Snaurova, Renata, primary, Nerreter, Silvia, primary, Teufel, Eva, primary, Garitano-Trojaola, Andoni, primary, Da Viá, Matteo, primary, Ruiz-Heredia, Yanira, primary, Rosenwald, Andreas, primary, Bolli, Niccolò, primary, Hajek, Roman, primary, Raab, Peter, primary, Raab, Marc S., primary, Weinhold, Niels, primary, Haferlach, Claudia, primary, Haaf, Thomas, primary, Martinez-Lopez, Joaquin, primary, Einsele, Hermann, primary, Rasche, Leo, primary, and Kortüm, K. Martin, primary

Published
2023
Full Text
View/download PDF

19. Supplementary Table 2 from Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

Author

Haertle, Larissa, primary, Barrio, Santiago, primary, Munawar, Umair, primary, Han, Seungbin, primary, Zhou, Xiang, primary, Simicek, Michal, primary, Vogt, Cornelia, primary, Truger, Marietta, primary, Fernandez, Rafael Alonso, primary, Steinhardt, Maximilian, primary, Weingart, Julia, primary, Snaurova, Renata, primary, Nerreter, Silvia, primary, Teufel, Eva, primary, Garitano-Trojaola, Andoni, primary, Da Viá, Matteo, primary, Ruiz-Heredia, Yanira, primary, Rosenwald, Andreas, primary, Bolli, Niccolò, primary, Hajek, Roman, primary, Raab, Peter, primary, Raab, Marc S., primary, Weinhold, Niels, primary, Haferlach, Claudia, primary, Haaf, Thomas, primary, Martinez-Lopez, Joaquin, primary, Einsele, Hermann, primary, Rasche, Leo, primary, and Kortüm, K. Martin, primary

Published
2023
Full Text
View/download PDF

26. Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-ATPase (PSMC) Gene Family in the Light of Proteasome Inhibitor Resistance in Multiple Myeloma

Author

Haertle, Larissa, primary, Buenache, Natalia, additional, Cuesta Hernández, Hipólito Nicolás, additional, Simicek, Michal, additional, Snaurova, Renata, additional, Rapado, Inmaculada, additional, Martinez, Nerea, additional, López-Muñoz, Nieves, additional, Sánchez-Pina, José María, additional, Munawar, Umair, additional, Han, Seungbin, additional, Ruiz-Heredia, Yanira, additional, Colmenares, Rafael, additional, Gallardo, Miguel, additional, Sanchez-Beato, Margarita, additional, Piris, Miguel Angel, additional, Samur, Mehmet Kemal, additional, Munshi, Nikhil C., additional, Ayala, Rosa, additional, Kortüm, Klaus Martin, additional, Barrio, Santiago, additional, and Martínez-López, Joaquín, additional

Published
2023
Full Text
View/download PDF

30. Genetic Alterations in Members of the Proteasome 26S Subunit, AAA-Atpase (PSMC) Gene Family Transmit Proteasome Inhibitor Resistance in Multiple Myeloma By Impacting the ADP/ATP Binding Pocket

Author

Haertle, Larissa, primary, Cuesta Hernandez, Hipolito Nicolas, additional, Buenache, Natalia Sofia, additional, Simicek, Michal, additional, Snaurova, Renata, additional, Rapado, Inmaculada, additional, Martinez, Nerea, additional, López-Muñoz, Nieves, additional, Sanchez-Pina, Jose Maria, additional, Colmenares, Rafael, additional, Sanchez-Beato, Margarita, additional, Piris, Miguel Angel, additional, Plaza Menacho, Ivan, additional, Kemal Samur, Mehmet, additional, Munshi, Nikhil C, additional, Ayala, Rosa, additional, Kortuem, K. Martin, additional, Barrio, Santiago, additional, and Martinez-Lopez, Joaquin, additional

Published
2022
Full Text
View/download PDF

31. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma

Author

Jelinek, Tomas, primary, Bezdekova, Renata, additional, Zihala, David, additional, Sevcikova, Tereza, additional, Anilkumar Sithara, Anjana, additional, Pospisilova, Lenka, additional, Sevcikova, Sabina, additional, Polackova, Petra, additional, Stork, Martin, additional, Knechtova, Zdenka, additional, Venglar, Ondrej, additional, Kapustova, Veronika, additional, Popkova, Tereza, additional, Muronova, Ludmila, additional, Chyra, Zuzana, additional, Hrdinka, Matous, additional, Simicek, Michal, additional, Garcés, Juan-Jose, additional, Puig, Noemi, additional, Cedena, Maria-Teresa, additional, Jurczyszyn, Artur, additional, Castillo, Jorge J., additional, Penka, Miroslav, additional, Radocha, Jakub, additional, Mateos, Maria Victoria, additional, San-Miguel, Jesús F., additional, Paiva, Bruno, additional, Pour, Ludek, additional, Rihova, Lucie, additional, and Hajek, Roman, additional

Published
2022
Full Text
View/download PDF

32. Single-Nucleotide Variants and Epimutations Induce Proteasome Inhibitor Resistance in Multiple Myeloma

Author

Haertle, Larissa, primary, Barrio, Santiago, additional, Munawar, Umair, additional, Han, Seungbin, additional, Zhou, Xiang, additional, Simicek, Michal, additional, Vogt, Cornelia, additional, Truger, Marietta, additional, Fernandez, Rafael Alonso, additional, Steinhardt, Maximilian, additional, Weingart, Julia, additional, Snaurova, Renata, additional, Nerreter, Silvia, additional, Teufel, Eva, additional, Garitano-Trojaola, Andoni, additional, Da Viá, Matteo, additional, Ruiz-Heredia, Yanira, additional, Rosenwald, Andreas, additional, Bolli, Niccolò, additional, Hajek, Roman, additional, Raab, Peter, additional, Raab, Marc S., additional, Weinhold, Niels, additional, Haferlach, Claudia, additional, Haaf, Thomas, additional, Martinez-Lopez, Joaquin, additional, Einsele, Hermann, additional, Rasche, Leo, additional, and Kortüm, K. Martin, additional

Published
2022
Full Text
View/download PDF

33. Mechanism of phospho-ubiquitin-induced PARKIN activation

Author

Wauer, Tobias, Simicek, Michal, Schubert, Alexander, and Komander, David

Subjects
Analysis, Ubiquitin-proteasome system -- Analysis, Ligases -- Analysis, Mitochondrial DNA -- Analysis
Abstract

The E3 ubiquitin ligase PARKIN (encoded by PARK2) and the protein kinase PINK1 (encoded by PARK6) are mutated in autosomal-recessive juvenile Parkinsonism (AR-JP) and work together in the disposal of [...]

Published
2015

34. Mutation landscape of multiple myeloma measurable residual disease: identification of targets for precision medicine

Author

Zátopková, Martina, Ševčíková, Tereza, Fanfani, Viola, Chyra, Zuzana, Říhová, Lucie, Bezděková, Renata, Žihala, David, Growková, Kateřina, Filipová, Jana, Černá, Lucie, Broskevičova, Lucie, Kryukov, Fedor, Minařík, Jiří, Smejkalová, Jana, Maisnar, Vladimír, Harvanová, Ĺubica, Pour, Luděk, Jungova, Alexandra, Popková, Tereza, Bago, Juli Rodriguez, Anilkumar Sithara, Anjana, Hrdinka, Matouš, Jelínek, Tomáš, Šimíček, Michal, Stracquadanio, Giovanni, and Hájek, Roman

Published
2022
Full Text
View/download PDF

35. More Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia-Like Multiple Myeloma.

Author

Jelinek, Tomas, Bezdekova, Renata, Zihala, David, Sevcikova, Tereza, Anilkumar Sithara, Anjana, Pospisilova, Lenka, Sevcikova, Sabina, Polackova, Petra, Stork, Martin, Knechtova, Zdenka, Venglar, Ondrej, Kapustova, Veronika, Popkova, Tereza, Muronova, Ludmila, Chyra, Zuzana, Hrdinka, Matous, Simicek, Michal, Garcés, Juan-Jose, Puig, Noemi, and Cedena, Maria-Teresa

Published
2023
Full Text
View/download PDF

36. Effect of Daratumumab-Containing Induction on CD34+ Hematopoietic Stem Cells before Autologous Stem Cell Transplantation in Multiple Myeloma

Author

Venglar, Ondrej, primary, Sevcikova, Tereza, additional, Sithara, Anjana Anilkumar, additional, Kapustova, Veronika, additional, Vrana, Jan, additional, Zihala, David, additional, Muronova, Ludmila, additional, Huvarova, Lucie, additional, Broskevicova, Lucie, additional, Simicek, Michal, additional, Koristek, Zdenek, additional, Hajek, Roman, additional, and Jelinek, Tomas, additional

Published
2021
Full Text
View/download PDF

37. Pathogenesis of Extramedullary Multiple Myeloma: From Resistance to Identification of Novel Therapeutic Targets

Author

Jelinek, Tomas, primary, Zihala, David, additional, Sevcikova, Tereza, additional, Kapustova, Veronika, additional, Sahinbegovic, Hana, additional, Sithara, Anjana Anilkumar, additional, Popkova, Tereza, additional, Plonkova, Hana, additional, Broskevicova, Lucie, additional, Vrana, Jan, additional, Zidlik, Vladimir, additional, Havel, Martin, additional, Koristek, Zdenek, additional, Bago, Juli R., additional, Simicek, Michal, additional, and Hajek, Roman, additional

Published
2021
Full Text
View/download PDF

39. Limited efficacy of daratumumab in multiple myeloma with extramedullary disease

Author

Jelinek, Tomas, primary, Sevcikova, Tereza, additional, Zihala, David, additional, Popkova, Tereza, additional, Kapustova, Veronika, additional, Broskevicova, Lucie, additional, Capkova, Lenka, additional, Rihova, Lucie, additional, Bezdekova, Renata, additional, Sevcikova, Sabina, additional, Zidlik, Vladimir, additional, Havel, Martin, additional, Plonkova, Hana, additional, Jungova, Alexandra, additional, Minarik, Jiri, additional, Stork, Martin, additional, Pour, Ludek, additional, Pavlicek, Petr, additional, Spicka, Ivan, additional, Maisnar, Vladimir, additional, Radocha, Jakub, additional, Simicek, Michal, additional, and Hajek, Roman, additional

Published
2021
Full Text
View/download PDF

40. P-344 Multiomics profiling of extramedullary multiple myeloma tumors and their microenvironment

Author

Jelinek, Tomas, Zihala, David, Sevcikova, Tereza, Sithara, Anjana Anilkumar, Kapustova, Veronika, Sahinbegovic, Hana, Venglar, Ondrej, Muronova, Ludmila, Broskevicova, Lucie, Bilek, Daniel, Popkova, Tereza, Plonkova, Hana, Vrana, Jan, Zidlik, Vladimir, Hurnik, Pavel, Havel, Martin, Hrdinka, Matous, Chyra, Zuzana, Simicek, Michal, and Hájek, Roman

Published
2023
Full Text
View/download PDF

41. Identification of Molecular Mechanisms Responsible for the Development of Extramedullary Disease in Myeloma and Potential Novel Therapeutic Targets Using Transcriptomic and Exome Profiling

Author

Zihala, David, primary, Sevcikova, Tereza, additional, Simicek, Michal, additional, Popkova, Tereza, additional, Plonkova, Hana, additional, Broskevicova, Lucie, additional, Vrana, Jan, additional, Bago, Juli R., additional, Hajek, Roman, additional, Stracquadanio, Giovanni, additional, and Jelinek, Tomas, additional

Published
2020
Full Text
View/download PDF

43. Venetoclax plus bortezomib and dexamethasone in heavily pretreated end‐stage myeloma patients without t(11;14): A real‐world cohort

Author

Jelinek, Tomas, primary, Popkova, Tereza, additional, Duras, Juraj, additional, Mihalyova, Jana, additional, Kascak, Michal, additional, Benkova, Katerina, additional, Plonkova, Hana, additional, Cerna, Lucie, additional, Koristek, Zdenek, additional, Simicek, Michal, additional, and Hajek, Roman, additional

Published
2020
Full Text
View/download PDF

46. Mechanisms of Proteasome Inhibitor Resistance Selected By Clonal Evolution in Multiple Myeloma

Author

Haertle, Larissa, primary, Barrio, Santiago, additional, Simicek, Michal, additional, Munawar, Umair, additional, Sanchez, Ricardo, additional, Bittrich, Max, additional, DaVia, Matteo, additional, Vogt, Cornelia, additional, Giesen, Nicola, additional, Garitano-Trojaola, Andoni, additional, Nerreter, Silvia, additional, Stuehmer, Thorsten, additional, Raab, Marc S., additional, Martinez Lopez, Joaquin, additional, Hajek, Roman, additional, Einsele, Hermann, additional, Rasche, Leo, additional, Haaf, Thomas, additional, and Kortüm, Martin, additional

Published
2019
Full Text
View/download PDF

47. Transcriptional profiling of circulating tumor cells in multiple myeloma: a new model to understand disease dissemination

Author

Garcés, Juan-Jose, primary, Simicek, Michal, additional, Vicari, Marco, additional, Brozova, Lucie, additional, Burgos, Leire, additional, Bezdekova, Renata, additional, Alignani, Diego, additional, Calasanz, Maria-Jose, additional, Growkova, Katerina, additional, Goicoechea, Ibai, additional, Agirre, Xabier, additional, Pour, Ludek, additional, Prosper, Felipe, additional, Rios, Rafael, additional, Martinez-Lopez, Joaquin, additional, Millacoy, Pamela, additional, Palomera, Luis, additional, Del Orbe, Rafael, additional, Perez-Montaña, Albert, additional, Garate, Sonia, additional, Blanco, Laura, additional, Lasa, Marta, additional, Maiso, Patricia, additional, Flores-Montero, Juan, additional, Sanoja-Flores, Luzalba, additional, Chyra, Zuzana, additional, Vdovin, Alexander, additional, Sevcikova, Tereza, additional, Jelinek, Tomas, additional, Botta, Cirino, additional, El Omri, Halima, additional, Keats, Jonathan, additional, Orfao, Alberto, additional, Hajek, Roman, additional, San-Miguel, Jesus F., additional, and Paiva, Bruno, additional

Published
2019
Full Text
View/download PDF

49. Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)

Author

Jelinek, Tomas, primary, Mihalyova, Jana, additional, Kascak, Michal, additional, Duras, Juraj, additional, Popkova, Tereza, additional, Benkova, Katerina, additional, Richterova, Petra, additional, Plonkova, Hana, additional, Zuchnicka, Jana, additional, Broskevicova, Lucie, additional, Huvarova, Lucie, additional, Cerna, Lucie, additional, Growkova, Katerina, additional, Simicek, Michal, additional, Havel, Martin, additional, Gumulec, Jaromir, additional, Navratil, Milan, additional, Koristek, Zdenek, additional, Paiva, Bruno, additional, and Hajek, Roman, additional

Published
2018
Full Text
View/download PDF

50. Cytarabine + G-CSF is more effective than cyclophosphamide + G-CSF as a stem cell mobilization regimen in multiple myeloma

Author

Jelinek, Tomas, primary, Adamusova, Lucie, additional, Popkova, Tereza, additional, Tvrda, Ivana, additional, Smejkalova, Jana, additional, Simicek, Michal, additional, Salounova, Dana, additional, Kascak, Michal, additional, Mihalyova, Jana, additional, Plonkova, Hana, additional, Duras, Juraj, additional, Navratil, Milan, additional, Hajek, Roman, additional, and Koristek, Zdenek, additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results